Founded in 1949, Medtronic has grown to become the world's largest independent medical technology company. At the core of all we do is our Mission: to alleviate pain, restore health and extend life. It provides a clear path for all employees as we work together to take Medtronic to the next level.
Medtronic was first incorporated April 23, 1957 and became a public company as the result of a convertible debenture offering. The first shares were issued under these debentures on December 17, 1959 to our company founders, Earl Bakken and Palmer Hermundslie. Medtronic shares were traded Over-the-Counter (OTC) until we were listed on the NASDAQ in 1964. Medtronic began trading on the New York Stock Exchange on November 21, 1977 and continues to be traded on the NYSE today under the ticker symbol MDT.
Three Analyses Presented at EuroPCR Demonstrate Device's Durability in Addressing Common Clinical Challenge PARIS -- May 22, 2013 -- Addressing one of the most common clinical challenges in the treatment of complex coronary artery disease, three separate analyses on the program for EuroPCR this week show how strongly the Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) performs in coronary bifurcation lesions over the long term. Bifurcation lesions occur when plaque builds up arou...
Proven Lead Expands Access to MRI for Patients with Slow Heartbeat TOLOCHENAZ - May 21, 2013 -- Medtronic today announced CE Mark (Conformité Européenne) and launch of its CapSureFix Novus(TM)5076 Lead, which is now approved in the EU for use in an MRI environment when paired with a Medtronic MR-Conditional pacemaker. The lead has not been approved for that use in the U.S. The CapSureFix Novus 5076 Lead, previously approved for use with Medtronic's non MR-Conditional pacemakers, has long been ...
Q4 Revenue of $4.5 Billion Grew 5% at Constant Currency; 4% as Reported Q4 Non-GAAP Diluted EPS Growth of 11%; GAAP Diluted EPS Growth of 1% Q4 International Revenue Grew 7% at Constant Currency; 4% as Reported FY13 Revenue of $16.6 Billion Grew 5% at Constant Currency; 3% as Reported FY13 Free Cash Flow of $4.4 Billion; GAAP Cash Flow from Operations of $4.9 Billion Company Sets Initial FY14 Revenue Growth Outlook and EPS Guidance MINNEAPOLIS - May 21, 2013 - Medtronic, Inc. (NYSE:...
